147 results on '"Kumada, Takashi"'
Search Results
2. Diagnostic performance of shear wave measurement in the detection of hepatic fibrosis: A multicenter prospective study
3. A comparative study of hepatic steatosis using two different qualitative ultrasound techniques measured based on magnetic resonance imaging‐derived proton density fat fraction
4. Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma
5. Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response
6. Effect of previous infection with hepatitis B virus on the incidence of hepatocellular carcinoma after sustained virologic response in patients with chronic hepatitis C virus infection
7. α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
8. Association of PPI and antibiotics with the clinical outcomes of HCC patients receiving atezolizumab and bevacizumab: A multicenter analysis
9. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
10. Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib
11. Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample
12. Combined ultrasound and magnetic resonance elastography predict hepatocellular carcinoma after hepatitis C virus eradication
13. Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus
14. Improved survival of viral hepatocellular carcinoma but not non‐viral hepatocellular carcinoma from 2000 to 2020: A multi‐centre cohort study of 6007 patients from high‐volume academic centres in Japan
15. Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct‐acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance
16. Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population
17. Long‐term persistence of hepatocarcinogenic potential of a non‐hypervascular hypointense nodule on EOB‐MRI after the eradication of hepatitis C virus
18. Safety, feasibility, and comfort of hepatic angiography and transarterial intervention with radial access for hepatocellular carcinoma
19. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib
20. Long‐term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis
21. Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct‐acting antiviral therapy and achieved sustained virological response
22. Reply to: ‘Long‐term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus‐related decompensated cirrhosis’
23. Pretreatment non‐hypervascular hypointense nodules on Gd‐EOB‐DTPA‐enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection
24. Abnormal fucosylation of alpha‐fetoprotein in patients with nonalcoholic steatohepatitis
25. Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis
26. Long‐term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus–related decompensated cirrhosis
27. Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis
28. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis
29. Serial changes in FIB‐4 score and hepatocarcinogenesis in hepatitis B patients treated with or without nucleot(s)ide analogue therapy
30. Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
31. Attenuation imaging based on ultrasound technology for assessment of hepatic steatosis: A comparison with magnetic resonance imaging‐determined proton density fat fraction
32. Editorial: impact of the introduction of direct-acting antiviral drugs on hepatocarcinogenesis-a prospective serial follow-up MRI study. Author’s reply
33. Long‐term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: An analysis using a Markov chain model
34. Impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis: a prospective serial follow-up MRI study
35. Use of hepatitis B virus core‐related antigen to evaluate natural history of chronic hepatitis B
36. Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
37. Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real‐world setting: A large, multicenter study from Japan
38. Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema
39. Liver stiffness does not affect ultrasound‐guided attenuation coefficient measurement in the evaluation of hepatic steatosis
40. Plasma and tumoral glypican‐3 levels are correlated in patients with hepatitis C virus‐related hepatocellular carcinoma
41. Editorial: the emergence of non-hypervascular hypointense nodules in Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C. Authors' reply
42. Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching
43. Real‐world experience of 12‐week direct‐acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection
44. The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C
45. Evaluation of 8‐week glecaprevir/pibrentasvir treatment in direct‐acting antiviral‐naïve noncirrhotic HCV genotype 1 and 2infected patients in a real‐world setting in Japan
46. Natural history of liver‐related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model
47. Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle‐aged patients with non‐alcoholic fatty liver disease
48. Circulating microRNA‐1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma
49. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study
50. Impact of albumin–bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time‐dependent receiver operating characteristic
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.